Andere talen Viridian Therapeutics, Inc.

Aandelen

VRDN

US92790C1045

Geschatte realtime Cboe BZX Andere beurzen 21:14:58 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
14,4 ^USD	+8,60%		+8,52%	-35,08%

21/03	VIRIDIAN THERAPEUTICS, INC. : B. Riley ontvangt een koopadvies	ZM
28/02	VIRIDIAN THERAPEUTICS, INC. : Wedbush ontvangt een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024	29/04
Foghorn Therapeutics Names Kristian Humer CFO	16/04
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm	29/03
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	05/03
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q4 Revenue $72,000	27/02
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	27/02
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	19/02
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	16/02
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	16/02
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer	16/02
Viridian Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4)	07/02
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	06/02
Viridian Therapeutics Prices Common Stock Offering at $21 per Share	18/01
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock	18/01
Viridian Therapeutics Starts Underwritten Stock Offering; Shares Fall After Hours	17/01
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock	17/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Viridian Therapeutics, Inc.

Aandelen

VRDN

US92790C1045

Andere talen

Filters